SEPNHIGH SIGNALRISK10-K

SEPN discontinued development of SEP-786 due to safety concerns and burned through nearly half its cash position while substantially increasing R&D spending.

The discontinuation of SEP-786 represents a significant pipeline setback for this biotech company, particularly given the disclosed safety issues requiring mechanistic investigation. While the company is advancing a next-generation compound, this creates execution risk and timeline delays. The substantial cash burn rate combined with meaningfully higher R&D expenses raises questions about runway duration and potential future financing needs.

Comparing 2026-03-09 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

SEPN's financial position shows mixed signals with cash reserves declining to $120.7M from $238.2M, representing nearly a 50% reduction that highlights aggressive spending. R&D expenses grew substantially to $97.6M, reflecting continued investment in pipeline development despite the SEP-786 discontinuation. The company's net loss improved modestly to $48.9M, while total assets increased to $596.2M, suggesting some offsetting value additions to the balance sheet.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-75.4%
$2.1M→$518K

Capex reduced 75.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

R&D Expense
P&L
+49.4%
$65.3M→$97.6M

R&D investment increased 49.4% — signals commitment to future product development, though near-term margin impact.

Cash & Equivalents
Balance Sheet
-49.3%
$238.2M→$120.7M

Cash declined 49.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
+31.9%
-$71.8M→-$48.9M

Net income grew 31.9% — bottom-line growth signals improving overall business health.

Total Assets
Balance Sheet
+30.6%
$456.6M→$596.2M

Asset base grew 30.6% — expansion through organic growth, acquisitions, or capital deployment.

Operating Income
P&L
+15.5%
-$80.8M→-$68.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Current Assets
Balance Sheet
+15.2%
$356.8M→$411.0M

Current assets grew 15.2% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-27
ADDED
In determining the market value of non-affiliate common stock, shares of the registrant s common stock beneficially owned by officers, directors and affiliates have been excluded.
This determination of affiliate status is not necessarily a conclusive determination for other purposes.
As of March 2, 2026, the registrant had 44,906,374 shares of common stock, $0.001 par value per share, outstanding.
federal trademark filings, including a registered trademark, and possess proprietary trademark rights in our name and logo that we use in connection with the operation of our business.
federal government shutdown or reduced resources, new or increased international tariffs and retaliatory tariffs, trade protection measures, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our common stock and our ability to access capital markets; and other risks and uncertainties, including those listed under the section titled Risk Factors in Part I, Item 1A of this Annual Report.
On February 18, 2025, we announced our decision to discontinue the development of SEP-786 and advance a next-generation oral small molecule PTH1R agonist.
In completed 28-day preclinical toxicology studies in rats and dogs, SEP-786 was generally well-tolerated, without predicted risk of bilirubin elevation.
In September 2025, we announced the findings from our post-discontinuation investigation that SEP-786 was a potent UGT1A1 inhibitor, which is a mechanism known to be associated with increases in unconjugated bilirubin.
In a follow-up cynomolgus monkey study of SEP-786, conducted after clinical discontinuation, we also observed elevated unconjugated bilirubin levels.
We announced in September 2025 that we had selected a new PTH1R development candidate, SEP-479.
REMOVED
The registrant s common stock began trading on the Nasdaq Global Market on October 25, 2024.
As of March 17, 2025, the registrant had 44,442,496 shares of common stock, $0.001 par value per share, outstanding.
federal trademark applications and unregistered trademarks, including our company name and logo, that we use in connection with the operation of our business.
On February 18, 2025, we announced our decision to discontinue the development of SEP-786 and advance a next-generation oral small molecule PTH1R agonist from our PTH1R program.
In completed 28-day preclinical toxicology studies, SEP-786 was generally well-tolerated, without predicted risk of bilirubin elevation.
In response to these Phase 1 events, we have initiated non-clinical studies to investigate the underlying mechanism behind the observed effect.
We plan to use any potential learnings from this investigation in the selection of the next-generation oral small molecule PTH1R agonist development candidate we plan to advance into clinical development.
Based on preclinical data observed to date, we believe that our PTH1R agonists have the potential to yield a differentiated treatment for hypoparathyroidism.
We are advancing multiple lead compounds towards selection of a next-generation oral small molecule PTH1R development candidate to complete IND-enabling studies and accelerate toward clinical development later this year.
Given our findings in Phase 1 for SEP-786, we plan to select a lead compound for advancement from a chemical series unrelated to the one that generated SEP-786.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →